AstraZeneca Acquires Omniose to Strengthen Vaccine Development Against Serious Bacterial Infections
Bengaluru: AstraZeneca has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious bacterial infections, and folded the business into its infectious diseases division, the target company said on Tuesday.
Financial terms of the deal were not disclosed
The acquisition follows a three-year exclusive research collaboration between the companies
The deal brings the US-based company's proprietary platform - which engineers and assembles bacterial vaccine components in a single process - under AstraZeneca's umbrella, boosting the Anglo-Swedish drugmaker's vaccine efforts
"Omniose's bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections," said Benjamin Moutier, AstraZeneca's senior vice president of infectious disease
Despite a diverse drug portfolio, AstraZeneca's on-market vaccine offerings are limited, and its CEO is refocusing on growth, with over 180 pipeline projects underpinning long-term ambitions
AstraZeneca discontinued its Covid-19 vaccine in 2024, but now offers Beyfortus for respiratory syncytial virus infections and FluMist for influenza
It is also exploring the development of cancer vaccines.
